Table 2.

Adverse events observed in >10% of patients overall.

Toxicity	Grade 1	Grade 2	Grade 3	Grade 4	Total
Fatigue	37 (63.9%)	5 (8.6%)	1 (1.7%)	0 (0%)	43 (74.1%)
Hypertension	8 (13.8%)	11 (19.0%)	8 (13.8%)	1 (1.7%)	28(48.3%)
Hot flashes	25 (43.1%)	1 (1.7%)	0 (0%)	0 (0%)	26 (44.8%)
Pain	19 (32.8%)	2 (3.4%)	1 (1.7%)	0 (0%)	22 (37.9%)
Hypokalemia	9 (15.5%)	2 (3.4%)	4 6.9%)	0 (0%)	15 (25.9%)
Back pain	11 (19.0%)	2 (3.4%)	0 (0%)	0 (0%)	13 (22.4%)
Limb edema	10 (17.2%)	1 (1.7%)	0 (0%)	0 (0%)	11 (19.0%)
Urinary frequency	7 (12.1%)	4 (6.9%)	0 (0%)	0 (0%)	11 (19.0%)
Aspartate aminotransferase increased	5 (8.6%)	4 (6.9%)	1 (1.7%)	0 (0%)	10 (17.2%)
Cough	8 (13.8%)	1 (1.7%)	0 (0%)	0 (0%)	9 (15.5%)
Constipation	8 (13.8%)	0 (0%)	0 (0%)	0 (0%)	8 (13.8%)
Dyspnea	8 (13.8%)	0 (0%)	0 (0%)	0 (0%)	8 (13.8%)
Nausea	6 (10.3%)	1 (1.7%)	0 (0%)	0 (0%)	7 (12.1%)
Renal and urinary disorders - Other	7 (12.1%)	0 (0%)	0 (0%)	0 (0%)	7 (12.1%)
Dizziness	6 (10.3%)	0 (0%)	0 (0%)	0 (0%)	6 (10.3%)
Musculoskeletal and connective tissue disorder - Other	6 (10.3%)	0 (0%)	0 (0%)	0 (0%)	6 (10.3%)
Limb pain	6 (10.3%)	0 (0%)	0 (0%)	0 (0%)	6 (10.3%)
Peripheral sensory neuropathy	4 (6.9%)	2 (3.4%)	0 (0%)	0 (0%)	6 (10.3%)
Maculopapular rash	6 (10.3%)	0 (0%)	0 (0%)	0 (0%)	6 (10.3%)

One patient experienced grade 2 heart failure, which was possibly treatment-related to treatment.